2000
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
Vassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease-Free SurvivalFluorescent Antibody TechniqueFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsProstatectomyProstate-Specific AntigenProstatic NeoplasmsRecurrenceRegression AnalysisReproducibility of ResultsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsProstate cancer patientsRadical prostatectomySerum PSACancer patientsPSA assaysUltrasensitive prostate specific antigenPre-operative PSAGroup of patientsSerial serum samplesEarly therapeutic interventionSeminal vesicle invasionSurgical margin positivityProstate-specific antigenRegular PSAUltrasensitive PSAPSA increaseMargin positivityClinical stageGleason scorePrognostic indicatorCapsular invasionTissue involvementTumor volumePatientsFast relapsep53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer
Angelopoulou K, Yu H, Bharaj B, Giai M, Diamandis E. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clinical Biochemistry 2000, 33: 53-62. PMID: 10693987, DOI: 10.1016/s0009-9120(99)00084-3.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsP53 gene mutationsP53 protein accumulationAntibody-negative patientsP53 antibodiesSeronegative patientsGene mutationsP53 accumulationBreast cancerProportion of patientsPrimary breast cancerFormer patient groupP53 protein overexpressionPatient groupAutoantibody generationProtein accumulationImmune responseSuch antibodiesDirect DNA sequencingCorresponding tumorsPatientsImmunofluorometric assayGene abnormalitiesCancerP53 gene
1998
Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients
Levesque M, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, Diamandis E. Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. International Journal Of Cancer 1998, 79: 147-152. PMID: 9583729, DOI: 10.1002/(sici)1097-0215(19980417)79:2<147::aid-ijc9>3.0.co;2-t.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceAntibody SpecificityBreast NeoplasmsCarcinoma, Ductal, BreastCombined Modality TherapyDisease-Free SurvivalFemaleFluorescent Antibody TechniqueHumansLymphatic MetastasisMiddle AgedMultivariate AnalysisNeoplasm StagingPredictive Value of TestsPrognosisReceptors, EstrogenReceptors, ProgesteroneRecurrenceSensitivity and SpecificityTime FactorsTumor Suppressor Protein p53ConceptsP53 proteinItalian breast cancer patientsProgesterone receptor expression statusMultivariate Cox regression analysisP53-negative patientsP53-positive patientsReceptor expression statusDisease-free survivalLymph node statusSteroid hormone receptor analysisCox regression analysisBreast cancer patientsEstrogen receptor expressionHormone receptor analysisCM-1 antibodySensitive immunofluorometric assayBreast cancer prognosisP53 protein accumulationOverall survivalPatient ageIndependent predictorsHistologic typeNode statusPrognostic valueShort patients
1995
Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75: 1327-1338. PMID: 7882283, DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinomaFemaleFluorescent Antibody TechniqueHumansMiddle AgedOvarian NeoplasmsPrognosisProportional Hazards ModelsSurvival AnalysisTumor Suppressor Protein p53ConceptsEpithelial ovarian carcinomaOvarian carcinomaMutant p53 proteinResidual tumorHistologic gradeOvarian cancerP53 proteinCancer relapseMutant p53 protein overexpressionLonger disease-free survivalKaplan-Meier survival curvesPostsurgical residual tumorDisease-free survivalEarly-stage diseaseSubset of patientsLow histologic gradeMutant p53 protein accumulationAdvanced-stage cancerDifferent clinical stagesP53-negative tumorsP53-positive tumorsP53 protein overexpressionPoor patient outcomesAnti-p53 antibodiesP53 protein accumulation